Sex hormones, vascular function and the outcome of hormone replacement therapy in cardiovascular disease

Future Cardiology

Volumn 3, Issue 3, 2007, Pages 283-300

  Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Calcium; Coronary artery disease; Endothelium; Estrogen; Hypertension; Nitric oxide; Progesterone; Protein kinase; Testosterone; Vascular smooth muscle

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CALCIUM ION; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; COUMESTROL; DIETHYLSTILBESTROL; ENDOTHELIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETANERCEPT; ETHINYLESTRADIOL; FULVESTRANT; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; NARINGENIN; NITRIC OXIDE; OGEN1; PLACEBO; PROGESTERONE; PROSTACYCLIN; PROTEIN KINASE C; RALOXIFENE; RHO KINASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CYTOSKELETON; DRUG DOSAGE FORM COMPARISON; DRUG METABOLISM; DRUG RECEPTOR BINDING; ESTROGEN BLOOD LEVEL; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEX DIFFERENCE; SMOOTH MUSCLE CONTRACTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 34248657596     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.3.3.283     Document Type: Review

References (90)

1. Mieres JH: Review of the American Heart Association's guidelines for cardiovascular disease prevention in women. Heart 92(Suppl. 3) iii10-iii13 (2006).
2. Hajjar I, Kotchen JM, Kotchen TA: Hypertension: trends in prevalence, incidence, and control. Annu. Rev. Public Health 27, 465-490 (2006).
3. Slater J, Rill V: Coronary artery disease: new insights into the pathophysiology, prevalence, and early detection of a monster menace. Semin. Ultrasound CT MR 25(2), 113-121 (2004).
4. Orshal JM, Khalil RA: Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286(2), R233-R249 (2004).
5. Reckelhoff JF: Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension 45(2), 170-174 (2005).
6. Mendelsohn ME: Genomic and nongenomic effects of estrogen in the vasculature. Am. J. Cardiol. 90(1A), 3F-6F (2002).
7. Mendelsohn ME, Karas RH: Molecular and cellular basis of cardiovascular gender differences. Science 308(5728), 1583-1587 (2005).
8. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P: Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342(8864), 133-136 (1993).
9. Grodstein F, Stampfer MJ, Manson JE et al.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl. J. Med. 335, 453-461 (1996).
10. Dubey RK, Imthurn B, Zacharia LC, Jackson EK: Hormone replacement therapy and cardiovascular disease: what went wrong and where do we go from here? Hypertension 44(6), 789-795 (2004).
11. Hulley S, Grady D, Bush T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280, 605-613 (1998).
12. Grady D, Herrington D, Bitter V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/ progestin replacement study follow up (HERS II). JAMA 288, 49-57 (2002).
13. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative radomized controlled trial. JAMA 288, 321-333 (2002).
14. Reckelhoff JF, Fortepiani LA: Novel mechanisms responsible for postmenopausal hypertension. Hypertension 43(5), 918-923 (2004).
15. Wynne FL, Khalil RA: Testosterone and coronary vascular tone: implications in coronary artery disease. J. Endocrinol. Invest. 26(2), 181-186 (2003).
16. Dan P, Cheung JC, Scriven DR, Moore ED: Epitope-dependent localization of estrogen receptor-α, but not -β, in en face arterial endothelium. Am. J. Physiol. Heart Circ. Physiol. 284, H1295-H1306 (2003).
17. Zhu Y, Bian Z, Lu P et al.: Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 295(5554), 505-508 (2002).
18. Figtree G, McDonald D, Watkins H, Channon K: Truncated estrogen receptor-α 46-kDa isoform in human endothelial cells. Circulation 107, 120-126 (2003).
19. Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F: Differentially expressed messenger RNA isoforms of the human estrogen receptor-α gene are generated by alternative splicing and promoter usage. Mol. Endocrinol. 12, 1939-1954 (1998).
20. Bolego C, Vegeto E, Pinna C, Maggi A, Cignarella A: Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 26(10), 2192-2199 (2006).
21. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS: Activities of estrogen receptor α- and β-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell Endocrinol. 206, 13-22 (2003).
22. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS: Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 140, 800-804 (1999).
23. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS: Antagonists selective for estrogen receptor α. Endocrinology 143, 941-947 (2002).
24. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ: Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 33(1 Pt 2), 177-182 (1999).
25. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK: 2-methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double block'ade of the cell cycle. Circ. Res. 99(3), 266-274 (2006).
26. 2+ entry mechanisms of coronary vasoconstriction. Arterioscler. Thromb. Vasc. Biol. 19(4), 1034-1040 (1999).
27. Song D, Arikawa E, Galipeau D, Battell M, McNeill JH: Androgens are necessary for the development of fructose-induced hypertension. Hypertension 43 (3), 667-672 (2004).
28. Chou TM, Sudhir K, Hutchison SJ et al: Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94, 2614-2619 (1996).
29. Kauser K, Rubanyi GM: Gender difference in endothelial dysfunction in the aorta of spontaneously hypertensive rats. Hypertension 25 (4 Pt 1), 517-523 (1995).
30. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW: Estrogen receptor-α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 103, 401-406 (1999).
31. Pare G, Krust A, Karas RH et al.: Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ. Res. 90, 1087-1092 (2002).
32. Darblade B, Pendaries C, Krust A et al.: Estradiol alters nitric oxide production in the mouse aorta through the α, but not β, estrogen receptor. Circ. Res. 90, 413-419 (2002).
33. Nilsson BO, Ekblad E, Heine T, Gustafsson JÅ: Increased magnitude of relaxation to oestrogen in aorta from oestrogen receptor-β knock-out mice. J. Endocrinol. 166, R5-R9 (2000).
34. Widder J, Pelzer T, von Poser-Klein C et al.: Improvement of endothelial dysfunction by selective estrogen receptor-α stimulation in ovariectomized SHR. Hypertension 42(5), 991-996 (2003).
35. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW: ERβ has nongenomic action in caveolae. Mol. Endocrinol. 16, 938-946 (2002).
36. Forte P, Kneale BJ, Mitne E, et al.: Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 32(4), 730-734 (1998).
37. 2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J. Biol. Chem. 281(37), 27335-27345 (2006).
38. Haynes MP, Sinha D, Russell KS et al.: Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ. Res. 87, 677-682 (2000).
39. Hernandez I, Delgado JL, Diaz J et al.: 17β-estradiol prevents oxidative stress and decreases blood pressure in ovarlectomized rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1599-R1605 (2000).
40. Wassmann K, Wassmann S, Nickenig G: Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ. Res. 97(10), 1046-1054 (2005).
41. Barber DA, Miller VM: Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am. J. Physiol. 273(5 Pt 2), H2325-H2332 (1997).
42. Egan KM, Lawson JA, Fries S et al.: COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957 (2004).
43. + channel activation. J. Appl. Physiol., 91, 2742-2750 (2001).
44. Honda H, Unemoto T, Kogo H: Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34(6), 1232-1236 (1999).
45. Bilsel AS, Moini H, Tetik E, Aksungar F, Kaynak B, Ozer A: 17β-estradiol modulates endothelin-1 expression and release in human endothelial cells. Cardiovasc. Res. 46, 579-584 (2000).
46. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M: Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension 37(2 Pt 2), 640-644 (2001).
47. David FL, Carvalho MH, Cobra AL et al.: Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 38(3 Pt 2), 692-696 (2001).
48. Collins P, Rosano GM, Sarrel PM et al.: 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 92 (1), 24-30 (1995).
49. Nickenig G, Strehlow K, Wassmann S et al.: Differential effects of estrogen and progesterone on AT1 receptor gene expression in vascular smooth muscle cells. Circulation 102, 1828-1833 (2000).
50. Dean SA, Tan J, O'Brien ER, Leenen FH: 17β-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288(3), R759-R766 (2005).
51. Salamanca DA, Khalil RA: Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem. Pharmacol. 70(11). 1537-1547 (2005).
52. 1 in vascular smooth muscle cells of female rat. Am. J. Pbysiol. Cell Pbysiol. 278 (4), C834-C844 (2000).
53. 1 during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J. Pharmacul. Exp. Ther. 291(1), 44-52 (1999).
54. 2+ efflux from female porcine coronary arterial smooth muscle. Am. J. Physiol. 276, H926-H934 (1999).
55. Kanashiro CA, Khalil RA: Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am. J. Physiol. Cell Physiol. 280(1), C34-C45 (2001).
56. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K: Nongenomic vasodilator action of progesterone on primate coronary arteries. J. Appl. Pbysiol. 92, 701-708 (2002).
57. Somlyo AP, Somlyo AV: Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. 522(Pt 2), 177-185 (2000).
58. Lee DL, Webb RC, Jin L: Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44(6), 796-799 (2004).
59. Noma K, Oyama N, Liao JK: Physiological role of ROCKs in the cardiovascular system. Am. J. Physiol. Cell Physiol. 290 (3), C661-C668 (2006).
60. Shimokawa H, Takeshita A: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 25(9), 1767-1775 (2005).
61. Simoncini T, Scorticati C, Mannella P et al.: Estrogen receptor-α interacts with Gα13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol. Endocrinol. 20(8), 1756-1771 (2006).
62. Chrissobolis S, Budzyn K, Marley PD, Sobey CG: Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. Stroke 35 (9), 2200-2205 (2004).
63. Cid MC, Esparza J, Schnaper HW et al.: Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. Angiogenesis 3(3), 271-280 (1999).
64. Register TC, Adams MR, Golden DL, Clarkson TB: Conjugated equine estrogens alone, but not in combination with medroxyprogesterone, acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler. Thromb. Vasc. Biol. 18(7), 1164-1171 (1998).
65. Wingrove CS, Garr E, Godsland IF, Stevenson JC: 17β-estradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim. Biophys. Acta 1406(2), 169-174 (1998).
66. Gao H, Liang M, Bergdahl A et al.: Estrogen attenuates vascular expression of inflammation associated genes and adhesion of monocytes to endothelial cells. Inflamm. Res. 55(8), 349-353 (2006).
67. Geraldes P, Gagnon S, Hadjadj S et al.: Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophill adhesion: an ERα-mediated pathway. Cardiovasc. Res. 71(3), 566-573 (2006).
68. Arenas IA, Armstrong SJ, Xu Y, Davidge ST: Tumor necrosis factor-α and vascular angiotensin II in estrogen-deficient rats. Hypertension 48(3), 497-503 (2006).
69. Sunday L, Tran MM, Krause DN, Duckles SP: Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am. J. Physiol. Endocrinol. Metab. 291(2), E261-E267 (2006).
70. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL: Dihydrotestosterone decreases tumor necrosis factor-α and lipopolysaccharide-induced inflammatory response in human endothelial cells. J. Clin. Endocrinol. Metab. 91(2), 546-554 (2006).
71. Wynne FL, Payne JA, Cain AE, Reckelhoff JF, Khalil RA: Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension 43(2), 405-412 (2004).
72. Grimes DA, Lobo RA: Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet. Gynecol. 100(6), 1344-1353 (2002).
73. Mikkola TS, Clarkson TB: Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. 53, 605-619 (2002).
74. Hsia J, Langer RD, Manson JE et al.: Conjugated equine estrogens and coronary heart disease. Arch. Intern. Med. 166, 357-365 (2006).
75. Naftolin F, Taylor HS, Karas R et al.: The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil. Steril. 81(6), 1498-1501 (2004).
76. Adams MR. Register TC, Golden DL, Wagner JD, Williams JK: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17(1), 217-221 (1997).
77. Ho JY, Chen MJ, Sheu WH et al.: Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod. 21(10), 2715-2720 (2006).
78. Sumino, H, Ichikawa S, Kasama S et al.: Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189(2), 436-442 (2006).
79. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR: Myocardial ischemia-reperfusion injury in estrogen receptor-α knockout and wild-type mice. Am. J. Physiol. Heart Circ. Physiol. 278, H1640-H1647 (2000).
80. Wang M, Crisostomo P, Wairluko GM, Meldrum DR: Estrogen receptor-α mediates acute myocardial protection in females. Am. J. Physiol. Heart Circ. Physiol. 290(6), H2204-H2209 (2006).
81. Rosano GM, Leonardo F, Pagnotta P et al.: Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99, 1666-1670 (1999).
82. 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin. Exp. Pharmacol. Physiol. 26(9), 707-715 (1999).
83. Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K: Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 44, 405-409 (2004).
84. Tsang SY, Yao X, Chan FL et al.: Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. Hypertension 44, 78-82 (2004).
85. Pinna C, Bolego C, Sanvito P et al.: Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta. J. Pharmacol. Exp. Ther. 319(3), 1444-1451 (2006).
86. Mosca L, Barrett-Connor E, Wenger NK et al.: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 88(4), 392-395 (2001).
87. Barrett-Connor E, Mosca L, Collins P et al.: Raloxifene Use for The Heart (RUTH) Trial Investigators: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355(2), 125-137 (2006).
88. Cassidy A, Albertazzi P, Lise Nielsen I et al.: Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc. Nutr. Soc. 65(1), 76-92 (2006).
89. Canonico M, Oger E, Plu-Bureau G et al.: Estrogen and Thromboembolism Risk (ESTHER) Study Group: Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115(7), 840-845 (2007).
90. Harman SM, Brinton EA, Cedars M et al.: KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8(1), 3-12 (2005).